Thomas Björk

Sökresultat

• 2021

  Thermodynamic modeling framework for prediction of tool wear and tool protection phenomena in machining

  Bjerke, A., Hrechuk, A., Lenrick, F., Markström, A., Larsson, H., Norgren, S., M'Saoubi, R., Björk, T. & Bushlya, V., 2021 nov. 15, I: Wear. 484-485, 203991.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Machining 100%
  • machining 80%
  • Wear 72%
  • Thermodynamics 66%
  • Wear of materials 56%
• 2015

  Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations

  Merseburger, A. S., Björk, T., Whitehouse, J. & Meani, D., 2015, I: Journal of Comparative Effectiveness Research. 4, 5, s. 447-453

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Absorbable Implants 100%
  • Leuprolide 91%
  • Gonadotropin-Releasing Hormone 65%
  • cancer 59%
  • Health Care Costs 58%
• 2013

  Modeling Freedom From Progression for Standard-Risk Medulloblastoma: A Mathematical Tumor Control Model With Multiple Modes of Failure

  Brodin, N. P., Vogelius, I. R., Björk, T., af Rosenschold, P. M. & Bentzen, S. M., 2013, I: International Journal of Radiation Oncology, Biology, Physics. 87, 2, s. 422-429

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Medulloblastoma 100%
  • progressions 91%
  • tumors 78%
  • confidence 64%
  • Uncertainty 60%

• Pituitary disease mortality: is it fiction?

  Erfurth, E. M., Siesjö, P. & Björk, T., 2013, I: Pituitary. 16, 3, s. 402-412

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Pituitary Diseases 100%
  • Hypopituitarism 59%
  • Pituitary Neoplasms 50%
  • Mortality 34%
  • Hormones 32%

• Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

  Vickers, A. J., Ulmert, D., Sjoberg, D. D., Bennette, C. J., Björk, T., Gerdtsson, A., Manjer, J., Nilsson, P., Dahlin, A., Bjartell, A., Scardino, P. T. & Lilja, H., 2013, I: BMJ: British Medical Journal. 346, s. f2023

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  Fil

  • Prostate-Specific Antigen 100%
  • Case-Control Studies 78%
  • Prostatic Neoplasms 77%
  • Neoplasm Metastasis 60%
  • Population 16%
  271 Nedladdningar (Pure)
• 2012

  A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index.

  Ulmert, D., Kaboteh, R., Fox, J. J., Savage, C., Evans, M. J., Lilja, H., Abrahamsson, P-A., Björk, T., Gerdtsson, A., Bjartell, A., Gjertsson, P., Höglund, P., Lomsky, M., Ohlsson, M., Richter, J., Sadik, M., Morris, M. J., Scher, H. I., Sjöstrand, K., Yu, A., & 3 andraSuurküla, M., Edenbrandt, L. & Larson, S. M., 2012, I: European Urology. 62, 1, s. 78-84

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostatic Neoplasms 100%
  • Bone and Bones 75%
  • Neoplasms 40%
  • Confidence Intervals 13%
  • Computer-Assisted Diagnosis 12%

• Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma.

  Blomstrand, M., Brodin, N. P., Munck af Rosenschöld, P., Vogelius, I. R., Sánchez Merino, G., Kiil-Berthlesen, A., Blomgren, K., Lannering, B., Bentzen, S. M. & Björk, T., 2012, I: Neuro-Oncology. 14, 7, s. 882-889

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Medulloblastoma 100%
  • Intensity-Modulated Radiotherapy 99%
  • Neurogenesis 86%
  • Proton Therapy 74%
  • Radiotherapy 56%
• 2011

  Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

  Christensson, A., Bruun, L., Björk, T., Cronin, A. M., Vickers, A. J., Savage, C. J. & Lilja, H., 2011, I: BJU International. 107, s. 1769-1774

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Kallikreins 100%
  • Prostate-Specific Antigen 80%
  • Tissue Kallikreins 65%
  • Prostatic Neoplasms 62%
  • Clinical Decision-Making 16%
• 2010

  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study

  Vickers, A. J., Cronin, A. M., Björk, T., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., Scardino, P. T., Ulmert, D. & Lilja, H., 2010 sep. 18, I: BMJ (Online). 341, 7773, c4521.

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Prostate-Specific Antigen 100%
  • Case-Control Studies 78%
  • Prostatic Neoplasms 77%
  • Neoplasm Metastasis 60%
  • Population 10%
• 2008

  Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population

  Ulmert, D., Serio, A. M., O'Brien, M. F., Becker, C., Eastham, J. A., Scardino, P. T., Björk, T., Berglund, G., Vickers, A. J. & Lilja, H., 2008, I: Journal of Clinical Oncology. 26, 6, s. 835-841

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostate-Specific Antigen 100%
  • Prostatic Neoplasms 77%
  • Population 38%
  • Neoplasms 31%
  • Preventive Medicine 11%

• Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

  Ulmert, D., Cronin, A. M., Björk, T., O'Brien, M. F., Scardino, P. T., Eastham, J. A., Becker, C., Berglund, G., Vickers, A. J. & Lilja, H., 2008, I: BMC Medicine. 6

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Prostate-Specific Antigen 100%
  • Case-Control Studies 78%
  • Prostatic Neoplasms 77%
  • Phlebotomy 39%
  • Neoplasms 26%
• 2007

  Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

  Lilja, H., Ulmert, D., Björk, T., Becker, C., Serio, A. M., Nilsson, J-A., Abrahamsson, P-A., Vickers, A. J. & Berglund, G., 2007, I: Journal of Clinical Oncology. 25, 4, s. 431-436

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Kallikreins 100%
  • Prostatic Neoplasms 62%
  • human kallikrein-related peptidase 3 45%
  • Tissue Kallikreins 36%
  • Phlebotomy 31%

• Prostataspecifikt antigen--den viktigaste cancermarkören. Diagnostik och uppföljning av prostatacancer har förändrats markant.

  Bratt, O. & Björk, T., 2007, I: Läkartidningen. 104, 46, s. 3460-3464

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

• The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy

  Vickers, A. J., Ulmert, D., Serio, A. M., Björk, T., Scardino, P. T., Eastham, J. A., Berglund, G. & Lilja, H., 2007, I: International Journal of Cancer. 121, 10, s. 2212-2217

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Tissue Kallikreins 100%
  • Tumor Biomarkers 81%
  • Prostatic Neoplasms 66%
  • Prostate-Specific Antigen 48%
  • human kallikrein-related peptidase 3 41%
• 2006

  Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.

  Bjartell, A., Johansson, R., Björk, T., Gadaleanu, V., Lundwall, Å., Lilja, H., Kjeldsen, L. & Udby, L., 2006, I: The Prostate. 66, Dec 30, s. 591-603

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Cysteine 100%
  • Prostate 88%
  • Prostatic Neoplasms 56%
  • Serum 48%
  • Proteins 39%

• Reproducibility and Accuracy of Measurements of Free and Total Prostate-Specific Antigen in Serum vs Plasma after Long-Term Storage at -20 {degrees}C.

  Ulmert, D., Becker, C., Nilsson, J-A., Piironen, T., Björk, T., Hugosson, J., Berglund, G. & Lilja, H., 2006, I: Clinical Chemistry. 52, 2, s. 235-239

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Prostate-Specific Antigen 100%
  • Serum 44%
  • Edetic Acid 29%
  • Sweden 27%
  • Clinical Chemistry 18%

• Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

  Tyrrell, C. J., Iversen, P., Tammela, T., Anderson, J., Björk, T., Kaisary, A. V. & Morris, T., 2006, I: BJU International. 98, 3, s. 563-572

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • bicalutamide 100%
  • Castration 74%
  • Prostatic Neoplasms 53%
  • Pharmacokinetics 50%
  • Prostate-Specific Antigen 15%
• 2004

  Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.

  Bruun, L., Ekberg, H., Björk, T., Lilja, H., Höglund, P. & Christensson, A., 2004, I: Journal of Urology. 171, 4, s. 1432-1435

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • human kallikrein-related peptidase 3 100%
  • Tissue Kallikreins 80%
  • Kidney Transplantation 54%
  • Prostate-Specific Antigen 19%
  • Renal Insufficiency 16%
• 2003

  Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors

  LoRusso, P. M., Herbst, R. S., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D., Kaye, S., Gianni, L., Harris, A., Björk, T., Maddox, A-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Feyereislova, A., Heyes, A., Averbuch, S. D., Ochs, J. & Baselga, J., 2003, I: Clinical Cancer Research. 9, 6, s. 2040-2048

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Gefitinib 100%
  • ErbB Receptors 75%
  • Protein-Tyrosine Kinases 72%
  • Non-Small Cell Lung Carcinoma 71%
  • Quality of Life 51%

• Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.

  Bruun, L., Björk, T., Lilja, H., Becker, C., Gustafsson, O. & Christensson, A., 2003, I: Nephrology Dialysis Transplantation. 18, 3, s. 598-602

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  Öppen tillgång

  • Peritoneal Dialysis 100%
  • Prostate-Specific Antigen 94%
  • Continuous Ambulatory Peritoneal Dialysis 81%
  • Renal Dialysis 80%
  • Prostatic Neoplasms 52%
• 2002

  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types

  Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Björk, T., Averbuch, S. D., Feyereislova, A., Swaisland, H., Rojo, F. & Albanell, J., 2002, I: Journal of Clinical Oncology. 20, 21, s. 4292-4302

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Gefitinib 100%
  • ErbB Receptors 75%
  • Protein-Tyrosine Kinases 72%
  • Pharmacokinetics 60%
  • Safety 46%
• 2001

  Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues

  Björk, T., Schalken, J., Wittjes, W., Ljungberg, B. & Lilja, H., 2001, I: The Prostate. 47, 1, s. 14-20

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • alpha 1-Antichymotrypsin 100%
  • Tissue Kallikreins 87%
  • Prostate-Specific Antigen 63%
  • Gonadotropin-Releasing Hormone 62%
  • Prostatic Neoplasms 49%
• 2000

  Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum

  Becker, C., Piironen, T., Pettersson, K., Björk, T., Wojno, K. J., Oesterling, J. E. & Lilja, H., 2000, I: Journal of Urology. 163, 1, s. 311-316

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Tissue Kallikreins 100%
  • Prostatic Neoplasms 56%
  • Prostate 32%
  • Serum 32%
  • Hyperplasia 28%
• 1999

  Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy

  Lilja, H., Haese, A., Björk, T., Friedrich, M. G., Piironen, T., Pettersson, K., Huland, E. & Huland, H., 1999, I: Journal of Urology. 162, 6, s. 2029-2035

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Tissue Kallikreins 100%
  • Prostatectomy 73%
  • Prostate-Specific Antigen 73%
  • Prostatic Neoplasms 56%
  • Pregnancy-Associated alpha 2-Macroglobulins 27%

• The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer

  Björk, T., Lilja, H. & Christensson, A., 1999, I: BJU International. 84, 9, s. 1021-1027

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostate-Specific Antigen 100%
  • Prostatic Neoplasms 77%
  • Odds Ratio 37%
  • Survival 32%
  • Multivariate Analysis 27%
• 1998

  Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum

  Björk, T., Ljungberg, B., Piironen, T., Abrahamsson, P-A., Pettersson, K., Cockett, A. T. & Lilja, H., 1998, I: Urology. 51, 1, s. 57-62

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • alpha 1-Antichymotrypsin 100%
  • Prostate-Specific Antigen 63%
  • Serum 28%
  • Prostatectomy 24%
  • Half-Life 13%
• 1996

  Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer

  Björk, T., Piironen, T., Pettersson, K., Lövgren, T., Stenman, U-H., Öesterling, J. E., Abrahamsson, P-A. & Lilja, H., 1996, I: Urology. 48, 6, s. 882-888

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostate-Specific Antigen 100%
  • Prostatic Neoplasms 77%
  • Serum 44%
  • Prostatic Hyperplasia 17%
  • Transurethral Resection of Prostate 9%

• Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues

  Sundkvist, G. M., Björk, T., Kjellström, H. & Lilja, B., 1996, I: Scandinavian Journal of Urology and Nephrology. 30, 1, s. 29-32

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostate-Specific Antigen 100%
  • Gonadotropin-Releasing Hormone 97%
  • Radionuclide Imaging 94%
  • Carcinoma 64%
  • Bone and Bones 58%
• 1995

  Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum

  Mitrunen, K., Pettersson, K., Piironen, T., Björk, T., Lilja, H. & Lövgren, T., 1995, I: Clinical Chemistry. 41, 8, s. 1115-1120

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Prostate-Specific Antigen 100%
  • Immunoassay 98%
  • Serum 44%
  • Monoclonal Antibodies 26%
  • alpha 1-Antichymotrypsin 19%
• 1994

  Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia

  Björk, T., Bjartell, A., Abrahamsson, P-A., Hulkko, S., di Sant'Agnese, A. & Lilja, H., 1994, I: Urology. 43, 4, s. 427-434

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • alpha 1-Antichymotrypsin 100%
  • Prostatic Hyperplasia 68%
  • Prostate-Specific Antigen 63%
  • Prostatic Neoplasms 49%
  • Transurethral Resection of Prostate 12%
• 1993

  Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium

  Bjartell, A., Björk, T., Matikainen, M-T., Abrahamsson, P-A., di Sant'Agnese, A. & Lilja, H., 1993, I: Urology. 42, 5, s. 502-510

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • alpha 1-Antichymotrypsin 100%
  • Prostate-Specific Antigen 63%
  • Prostate 52%
  • Epithelium 47%
  • In Situ Hybridization 12%

• Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

  Christensson, A., Björk, T., Nilsson, O., Dahlen, U., Matikainen, M. T., Cockett, A. T., Abrahamsson, P. A. & Lilja, H., 1993, I: Journal of Urology. 150, 1, s. 100-105

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • alpha 1-Antichymotrypsin 100%
  • Prostate-Specific Antigen 63%
  • Prostatic Neoplasms 49%
  • Serum 28%
  • Prostatic Hyperplasia 17%
• 1989

  Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women

  Abrahamsson, P-A., Andersson, C., Björk, T., Fernlund, P., Lilja, H., Murne, A. & Weiber, H., 1989, I: Clinical Chemistry. 35, 7, s. 1497-1503

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • beta-microseminoprotein 100%
  • Radioimmunoassay 51%
  • Prostate 27%
  • Serum 24%
  • Urine 23%

• Use of ciprofloxacin in patients undergoing transurethral prostatic surgery

  Hellsten, S., Forsgren, A., Björk, T. & Grabe, M., 1989, I: Scandinavian Journal of Infectious Diseases. Supplementum. 60, s. 104-107

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Bacteriuria 100%
  • Ciprofloxacin 81%
  • Anti-Bacterial Agents 10%
  • Therapeutics 2%
• 1987

  Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery

  Grabe, M., Forsgren, A., Björk, T. & Hellsten, S., 1987, I: European Journal of Clinical Microbiology and Infectious Diseases. 6, 1, s. 11-17

  Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

  • Bacteriuria 100%
  • Ciprofloxacin 81%
  • Prostatic Hyperplasia 17%
  • Prostatic Neoplasms 12%
  • Anti-Bacterial Agents 10%